Clinical Research Directory
Browse clinical research sites, groups, and studies.
Predictive Proteomic Factors of the Response to Concomitant Radiochemotherapy in Esophageal Cancer
Sponsor: Centre Oscar Lambret
Summary
The scope of the trial is to predict the early complete clinical response to exclusive concomitant radiochemotherapy in esophageal cancer by the study of the pre- and per- therapeutic proteomic profile.
Official title: Study of Predictive Proteomic Factors of the Response to Exclusive Concomitant Radiochemotherapy in Oesophageal Cancer
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2007-10
Completion Date
2011-12
Last Updated
2026-09-17
Healthy Volunteers
No
Conditions
Interventions
Blood sampling
Before any study treatment, 14 days after radiotherapy, 15 weeks after radiotherapy
Radiation
Week 1 to week 5-6 1.8-2 Gys/fraction, 5 days a week for a total of 5 to 6 weeks
Chemotherapy (Fluorouracil and Cisplatin)
At weeks 1, 5, 8 and 11 * Day 1 to day 4: Fluorouracil 1 gr/m²/day * Day 1 or 2: Cisplatin 75 mg/m²
Locations (6)
Centre Paul Papin
Angers, France
Centre Hospitalier Universitaire
Brest, France
Centre François BACLESSE
Caen, France
Centre Oscar Lambret
Lille, France
Centre Eugène Marquis
Rennes, France
CHU - Hopital Charles Nicolle
Rouen, France